00399 INNOVATIVE PHAR
- 0.209
- +0.009+4.50%
INNOVATIVE PHAR News
Pioneer Pharmaceutical Biotech announced that the placement agreement has expired and that the placement matters will not be carried out
Pilot Pharmaceutical Biotechnology (00399) issued an announcement. Since the prerequisites contained in the placement agreement were not fully reached or satisfied before April 18, 2024 (that is, the final deadline of the placement agreement), the placement agreement has expired and the placement matters will not proceed. All rights, obligations and liabilities of the contracting party to the placement agreement will cease and end, and the contracting party will not file any claims against the other party, except for any prior breach of the placement agreement before the termination of the placement agreement. The announcement stated that the expiration of the placement agreement will not have any significant adverse impact on the company's current operations and financial situation.
Pioneer Pharmaceutical Biotechnology (00399.HK): The placement agreement has expired
Gelonghui, April 19 | Pilot Pharmaceutical Biotechnology (00399.HK) announced that since the prerequisites contained in the placement agreement were not fully reached or satisfied before April 18, 2024, the placement agreement has expired and the placement matters will not proceed.
Pilot Pharmaceutical Biotechnology (00399) issued 55 million shares due to the exercise of the right to convert convertible bonds
Pilot Pharmaceutical Biotechnology (00399) issued an announcement according to the exercise of convertible shares issued on April 30, 2015...
Pilot Pharmaceutical Biotechnology (00399) issued approximately 99 million shares due to the conversion of convertible bonds
Pilot Pharmaceutical Biotechnology (00399) issued an announcement. The company issued on December 31, 2014 in accordance with the exercise...
Innovative Pharmaceutical Biotech (HKG:399) Is Posting Solid Earnings, But It Is Not All Good News
Solid profit numbers didn't seem to be enough to please Innovative Pharmaceutical Biotech Limited's (HKG:399) shareholders. Our analysis suggests they may be concerned about some underlying details.
領航醫藥生物科技：中期報告 2023-2024
Innovative Pharmaceutical Biotech Returns to Fiscal H1 Attributable Profit
Innovative Pharmaceutical Biotech (HKG:0399) returned to an attributable profit of HK$193.7 million in the first fiscal half from a loss of HK$115.7 million in the year-ago period, a Wednesday filing
Pilot Pharmaceuticals Biotech Announces Interim Results Profit Attributable to Owners of Approximately HK$194 million
Pilot Pharmaceutical Biotech (00399) announced results for the six months ended September 30, 2023, with revenue of HK$3.727 million, a year-on-year decrease of 9.93%; profit attributable to company owners of approximately HK$194 million, loss attributable to the same period last year of approximately HK$116 million; and basic earnings per share of HK$13.23 cents.
Pilot Pharmaceutical Biotechnology (00399.HK)'s mid-term earnings of about HK$3.7 million decreased by about 9.7% year-on-year
Gelonghui November 29丨Pilot Pharmaceutical Biotechnology (00399.HK) announced that for the six months ended September 30, 2023, the company's revenue was approximately HK$3,700,000, a decrease of about 9.7% over the previous year. The decrease was mainly due to a decrease in the operations of the Beauty Equipment and Products Trading Division during the current financial period. The Group recorded a profit of approximately HK$193,700,000 attributable to company owners during the period, while a loss of HK$115,700,000 was recorded in the previous financial period. The conversion of losses to profits was mainly due to non-cash items arising from the completion of the third revision of Convertible Bonds III during the current financial period.
INNOVATIVE PHAR: ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
Innovative Pharmaceutical Biotech to Return to Profit in Fiscal H1
Innovative Pharmaceutical Biotech (HKG:0399) expects to book a profit attributed to shareholders of between HK$100 million and HK$200 million for the fiscal first half, turning around from the loss of
INNOVATIVE PHAR: Profit Alert
Pilot Pharmaceutical Biotechnology (00399.HK) will hold a board meeting on November 29 to approve the interim results
Gelonghui November 14|Pilot Pharmaceutical Biotechnology (00399.HK) announced that a board meeting will be held on November 29, 2023 to consider and approve the comprehensive interim results of the company and its subsidiaries for the six months ended September 30, 2023.
Innovative Pharmaceutical Eyes Majority Stake in US Neurotechnology Firm
Innovative Pharmaceutical Biotech (HKG:0399) is in negotiations to acquire a majority stake in US-based Niraxx, which is developing wearables for brain health and related disorders using non-invasive
Niraxx Develops At-Home, Self-Administered Brain Neurostimulation Hybrid Virtual Platform
Niraxx Develops At-Home, Self-Administered Brain Neurostimulation Hybrid Virtual Platform
Innovative Pharmaceutical to Issue Convertible Bonds to Acquire Stake
Innovative Pharmaceutical to Issue Convertible Bonds to Acquire Stake
Innovative Pharmaceutical Biotech Plans to Acquire a Majority Stake in U.S. Based Company Niraxx
Innovative Pharmaceutical Biotech Plans to Acquire a Majority Stake in U.S. Based Company Niraxx
Pilot Pharmaceutical Biotechnology (00399.HK): Termination of subscription agreement
GLONGHUI, September 4 | Pilot Pharmaceutical Biotechnology (00399.HK) announced that after further negotiations and discussions, the subscriber failed to fulfill its responsibilities under the subscription agreement. After considering (including) current market conditions, the company and subscribers have decided not to continue with the subscription matters. Having considered the above, on September 4, 2023, the company and the subscriberer entered into a deed of termination. Based on this, the contracting party to the subscription matter agreed that the subscription agreement would be terminated from September 4, 2023, and that all rights, rights, obligations and liabilities of the contracting party would be terminated, and that no contracting party could give to the other party arising out of or relating to the subscription agreement
INNOVATIVE PHAR: Annual Report 2023
Pilot Pharmaceutical Biotechnology (00399.HK) plans to issue HK$55.5 million convertible bonds
On July 28, July 28丨Pilot Pharmaceutical Biotechnology (00399.HK) announced that on July 27, 2023, the company signed a subscription agreement with the subscriber (that is, Dr. Mao Yumin). Based on this, the subscriber conditionally agreed to subscribe for convertible bonds with a principal amount of HK$55.5 million. Assuming that all convertible bonds are converted at a convertible share price of HK$0.211 per share (subject to adjustment), a maximum of about 263 million converted shares will be distributed and issued, which is equivalent to approximately 17.96% of the company's issued share capital of about 17.96% and the issued share capital expanded by the distribution and issuance of converted shares of about 15.23
Analysis
Price Target
No Data
